Lacombe: COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency

COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency

Lacombe et al., medRxiv, doi:10.1101/2022.08.09.22278329 (Preprint), CORIPLASM, NCT04345991 (history)

Lacombe et al., COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying.., medRxiv, doi:10.1101/2022.08.09.22278329 (Preprint), CORIPLASM, NCT04345991

Aug 2022 Source PDF

Twitter
Facebook

All Studies Meta

RCT 120 hospitalized patients in France, showing no significant difference in outcomes with convalescent plasma treatment, with the exception of lower mortality in the subgroup of immunosuppressed patients.

Important missing comments or errors? Let us know.

risk of death, 49.0% lower, HR 0.51, p = 0.16, treatment 7 of 60 (11.7%), control 12 of 60 (20.0%), NNT 12, adjusted per study, day 28.

risk of death, 64.0% lower, HR 0.36, p = 0.04, treatment 4 of 22 (18.2%), control 11 of 27 (40.7%), NNT 4.4, adjusted per study, day 28, immunocompromised.

risk of progression, 68.3% higher, RR 1.68, p = 0.18, treatment 13 of 60 (21.7%), control 8 of 60 (13.3%), adjusted per study, odds ratio converted to relative risk, WHO-CPS ≥6, day 4, primary outcome.

risk of progression, 4.0% higher, HR 1.04, p = 0.89, treatment 19 of 60 (31.7%), control 20 of 60 (33.3%), NNT 60, adjusted per study, ventilation, additional immunomodulators, or death, day 14, primary outcome.

hospitalization time, 6.7% higher, relative time 1.07, p = 0.99, treatment 60, control 60.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Lacombe et al., 10 Aug 2022, Randomized Controlled Trial, France, preprint, 33 authors, study period 16 April, 2020 - 21 April, 2021, trial NCT04345991 (history) (CORIPLASM).

Contact: karine.lacombe2@aphp.fr, raphael.porcher@aphp.fr.

All Studies All Outcomes Submit Updates or Corrections

This Paper Conv. Plasma All

Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.08.09.22278329; this version posted October 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency Running title: Convalescent plasma to treat COVID-19 Karine Lacombe,1 Thomas Hueso,2 Raphael Porcher,3 Arsène Mekinian,4 Thibault Chiarabini,5 Sophie Georgin-Lavialle,6 Florence Ader,7 Julien Saison,8 Guillaume Martin Blondel,9 Nathalie De Castro,10 Fabrice Bonnet,11 Charles Cazanave,12 Anne François,13 Pascal Morel,13 Olivier Hermine14, Valérie Pourcher,15 Marc Michel,16 Xavier Lescure,17 Nora Soussi,18 Philippe Brun,19 Fanny Pommeret,20 Pierre-Olivier Sellier,21 Stella Rousset,22 Lionel Piroth,23 Jean-Marie Michot,24 Gabriel Baron,3 Xavier De Lamballerie25 Xavier Mariette,26 Pierre-Louis Tharaux, 27 Matthieu Resche-Rigon,28 Philippe Ravaud,4 Tabassome Simon,29 Pierre Tiberghien,13,30 1 Sorbonne Université, IPLESP Inserm UMR-S1136, Paris, France ; service de maladies infectieuses et tropicales, Hôpital Saint-Antoine, AP-HP, Paris, France 2 3 Département d’hématologie clinique, Gustave Roussy, Université Paris-Saclay, Villejuif, France Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS-UMR1153), Inserm / Université Paris, Centre d'épidémiologie clinique, Hôpital Hôtel-Dieu, AP-HP, Paris, France 4 Sorbonne Université, Hôpital Saint Antoine, service de médecine interne et Inflammation-Immunopathology- BioInStherapy Department, AP-HP, Paris, France 5 6 7 Infectious Diseases Department, Hôpital Saint-Antoine, AP-HP, Paris, France Sorbonne Université, Service de médecine interne, hôpital Tenon, AP-HP, Paris, France Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Département des Maladies Infeceuses et Tropicales, Lyon, France ; Université Claude Bernard Lyon 1, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Lyon, France. 8 9 Service de Maladies infectieuses, Centre Hospitalier de Valence, Valence, France Service des Maladies Infectieuses et Tropicales, CHU de Toulouse & Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France 10 11 12 13 14 15 Département des Maladies Infectieuses, Hôpital Saint-Louis, AP-HP, Paris, France CHU de Bordeaux and Bordeaux University, Bordeaux Population Health, INSERM U1219, Bordeaux, France Service de maladies infectieuses et tropicales, CHU Pellegrin, Bordeaux, France Etablissement Français du Sang, La Plaine Saint-Denis, France Université de Paris-Cité, Paris, France ; Département d’hématologie, Hôpital Necker, AP-HP, Paris, France Sorbonne Université, IPLESP Inserm UMR-S1136, Paris, France ; service de maladies infectieuses et tropicales, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris, France 16 Université de Paris Est Créteil, France ; Département de Médecine interne, Hôpital Henri Mondor, AP-HP, Créteil France 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.08.09.22278329; this version posted October 27, 2022. The copyright holder for this preprint (which was not certified..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit